Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann; K. Fizazi; N. Shore; T. L. Tammela; A. Ulys; E. Vjaters; S. Polyakov; M. Jievaltas; M. Luz; B. Alekseev; I. Kuss; M. -A. Le Berre; O. Petrenciuc; A. Snapir; T. Sarapohja; M. R. Smith

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

M. Boegemann, K. Fizazi, N. Shore, T. L. Tammela, A. Ulys, E. Vjaters, S. Polyakov, M. Jievaltas, M. Luz, B. Alekseev, I. Kuss, M. -A. Le Berre, O. Petrenciuc, A. Snapir, T. Sarapohja, M. R. Smith

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	149
Pages (from-to)	225-225
Number of pages	1
Journal	Oncology Research and Treatment
Volume	43
Issue number	SUPPL 4
Publication status	Published - Oct 2020
Externally published	Yes
Event	Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology - virtual /Congress Center Basel, Basel, Switzerland Duration: 9 Oct 2020 → 11 Oct 2020 https://www.messe-basel.com/en/news/2020/dgho-in-basel-switzerlands-first-large-scale-digital-congress/ https://boardroom.global/physicians-can-still-get-together-in-basel/

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Boegemann, M., Fizazi, K., Shore, N., Tammela, T. L., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, M. -A., Petrenciuc, O., Snapir, A., Sarapohja, T., & Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). Oncology Research and Treatment, 43(SUPPL 4), 225-225. [149].

@article{398242a565d9439bbce3bbffdda08409,

title = "Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)",

author = "M. Boegemann and K. Fizazi and N. Shore and Tammela, {T. L.} and A. Ulys and E. Vjaters and S. Polyakov and M. Jievaltas and M. Luz and B. Alekseev and I. Kuss and {Le Berre}, {M. -A.} and O. Petrenciuc and A. Snapir and T. Sarapohja and Smith, {M. R.}",

year = "2020",

month = oct,

language = "English",

volume = "43",

pages = "225--225",

journal = "Oncology Research and Treatment",

issn = "2296-5270",

publisher = "S. Karger AG",

number = "SUPPL 4",

note = "Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology ; Conference date: 09-10-2020 Through 11-10-2020",

url = "https://www.messe-basel.com/en/news/2020/dgho-in-basel-switzerlands-first-large-scale-digital-congress/, https://boardroom.global/physicians-can-still-get-together-in-basel/",

}

Boegemann, M, Fizazi, K, Shore, N, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, M-A, Petrenciuc, O, Snapir, A, Sarapohja, T & Smith, MR 2020, 'Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)', Oncology Research and Treatment, vol. 43, no. SUPPL 4, 149, pp. 225-225.

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC). / Boegemann, M.; Fizazi, K.; Shore, N. et al.
In: Oncology Research and Treatment, Vol. 43, No. SUPPL 4, 149, 10.2020, p. 225-225.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

AU - Boegemann, M.

AU - Fizazi, K.

AU - Shore, N.

AU - Tammela, T. L.

AU - Ulys, A.

AU - Vjaters, E.

AU - Polyakov, S.

AU - Jievaltas, M.

AU - Luz, M.

AU - Alekseev, B.

AU - Kuss, I.

AU - Le Berre, M. -A.

AU - Petrenciuc, O.

AU - Snapir, A.

AU - Sarapohja, T.

AU - Smith, M. R.

PY - 2020/10

Y1 - 2020/10

UR - https://www-webofscience-com.db.rsu.lv/wos/woscc/full-record/WOS:000575955000507

M3 - Meeting Abstract

SN - 2296-5270

VL - 43

SP - 225

EP - 225

JO - Oncology Research and Treatment

JF - Oncology Research and Treatment

IS - SUPPL 4

M1 - 149

T2 - Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology

Y2 - 9 October 2020 through 11 October 2020

ER -

Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

Field of Science*

Publication Type*

UN SDGs

Other files and links

Cite this